跳至主要内容
临床试验/NCT03386994
NCT03386994已完成不适用

Observational Analysis on the Socio-economic Impact of IPF in Spain

Boehringer Ingelheim31 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2017年11月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
204
试验地点
31
主要终点
Idiopathic Pulmonary Fibrosis (IPF)-Related Costs

研究概览

简要总结

Descriptive prospective non-interventional multicenter study based on newly collected data of Idiopathic Pulmonary Fibrosis patients followed-up for one year in secondary care settings (Pulmonology Services)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Female and male patients ≥ 40 years of age
  • Patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) according to last ATS/ERS/JRS/ALAT IPF guideline for diagnosis and management consensus
  • Written informed consent prior to participation

排除标准

  • Inability for the patient to understand or complete the written Inform Consent or patients questionnaires or to understand Spanish
  • Current participation in any clinical trial
  • Patients for whom further follow-up is not possible at the enrolling site

结局指标

主要结局

Idiopathic Pulmonary Fibrosis (IPF)-Related Costs

时间窗: 12 months. (At baseline visit (T0), at 6 months visit (T6) and at 12 month visit (T12)).

The total annual IPF-related costs were obtained as the sum of direct health costs, direct non-health costs and indirect costs. IPF-related costs were quantified for each patient over the follow-up period of 12 months. The direct health and direct non-health costs were calculated as the sum of the costs of medical visits, emergency room visits, hospital admissions, outpatient tests, non-pharmacological treatments and pharmacological treatments and the sum of transport costs, paid caregivers costs, orthopedic material costs, financial aid, and structural changes cost. The indirect costs included number of IPF related days off work and time dedicated to patient care with IPF (informal caregiver). The opportunity cost method was used to calculate informal care costs. The indirect costs were estimated by applying salary costs based on the latest data published by the Spanish Instituto Nacional de Estadística from the salary structure survey, adjusted to age.

次要结局

  • Number of Idiopathic Pulmonary Fibrosis (IPF)-Patients With Acute Exacerbations Along One Year(12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).)
  • Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through Saint George´s Respiratory Questionaire (SGRQ)(12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).)
  • Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through EuroQoL Visual Analogue Scale (EQ-VAS)(12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).)
  • Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Subgroup: Predicted FVC 50-80% at T0(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF), Through Barthel Index(12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).)
  • Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T0(12 months (At baseline visit (T0) and at 12 month visit (T12)).)
  • Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Total Annual Acute Exacerbation-related Costs(12 months. (At baseline visit (T0), at 6 months visit (T6) at 12 month visit (T12)).)
  • Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T0(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Impact of Disease on the Patients Caregiver Through Zarit Burden Interview Questionaire(12 months. (At baseline visit (T0), at 6 month visit (T6), at 12 month visit (T12)).)
  • Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Overall FVC Patient Group(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)
  • Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0(12 months. (At baseline visit (T0) and at 12 month visit (T12)).)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (31)

Loading locations...

相似试验

OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study | 临床试验